

Jihye Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4526680/publications.pdf>

Version: 2024-02-01

34
papers

2,057
citations

430442

18
h-index

476904

29
g-index

36
all docs

36
docs citations

36
times ranked

3704
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic complexity of multiple myeloma and its clinical implications. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 100-113.	12.5	413
2	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	7.7	263
3	Prognostic role of circulating exosomal miRNAs in multiple myeloma. <i>Blood</i> , 2017, 129, 2429-2436.	0.6	214
4	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020, 1, 493-506.	5.7	209
5	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	0.8	110
6	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	5.8	98
7	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017, 19, 218-224.	2.9	92
8	Transcriptional mediators of treatment resistance in lethal prostate cancer. <i>Nature Medicine</i> , 2021, 27, 426-433.	15.2	90
9	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84
10	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 2487-2499.	3.9	80
11	<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 2094-2100.	0.4	71
12	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	53
13	Platelets Enhance Multiple Myeloma Progression via IL-1 β Upregulation. <i>Clinical Cancer Research</i> , 2018, 24, 2430-2439.	3.2	44
14	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	2.9	40
15	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. <i>Leukemia</i> , 2018, 32, 1739-1750.	3.3	34
16	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021, 36, 109665.	2.9	24
17	<i>Pseudomonas aeruginosa</i> High-Level Resistance to Polymyxins and Other Antimicrobial Peptides Requires <i>cprA</i> , a Gene That Is Disrupted in the PAO1 Strain. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5377-5387.	1.4	23
18	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. <i>Leukemia</i> , 2019, 33, 266-270.	3.3	21

#	ARTICLE	IF	CITATIONS
19	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	5.8	19
20	Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. <i>Nature Cancer</i> , 2021, 2, 1102-1112.	5.7	19
21	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018, 132, 154-154.	0.6	19
22	Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival. <i>Cancer Research</i> , 2021, 81, 3971-3984.	0.4	11
23	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. <i>Blood</i> , 2016, 128, 197-197.	0.6	8
24	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	0.6	6
25	A novel in vivo model for studying conditional dual loss of BLIMP1 and p53 in B-cells, leading to tumor transformation. <i>American Journal of Hematology</i> , 2017, 92, E138-E145.	2.0	3
26	Driver Mutation in Waldenstrom's Macroglobulinemia and Their Clonal Heterogeneity during Progression and Relapse. <i>Blood</i> , 2016, 128, 1092-1092.	0.6	2
27	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. <i>Blood</i> , 2016, 128, 1137-1137.	0.6	2
28	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. <i>Blood</i> , 2018, 132, 2603-2603.	0.6	1
29	Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression. <i>Blood</i> , 2018, 132, 3896-3896.	0.6	1
30	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. <i>Blood</i> , 2016, 128, 237-237.	0.6	0
31	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. <i>Blood</i> , 2016, 128, 4169-4169.	0.6	0
32	The Lysine Acetyltransferase Tip60 Is Required for Hematopoietic Stem Cell Maintenance. <i>Blood</i> , 2018, 132, 2554-2554.	0.6	0
33	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. <i>Blood</i> , 2018, 132, 55-55.	0.6	0
34	In Vivo Modeling of Clonal Competition Using CRISPR-Based Gene Editing Reveals Novel Fitness Variables in Multiple Myeloma. <i>Blood</i> , 2018, 132, 57-57.	0.6	0